CYDY · CytoDyn Inc. · Executive Compensation
$0.25
+0.02 (+9.51%)
At close · Oct 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Oct 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company had an accumulated deficit of approximately $950.4 million as of August 31, 2026. These factors, among several others, raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Oct 14, 2026
Market Cap
$367.38M
Shares
1.47B
Volume · Oct 19
6.48M
Avg daily vol (3M)
1.6M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2026
| Executive | Role | Total |
|---|---|---|
| Robert E. Hoffman | Chief Financial Officer | $1,899,609 |
| Jacob P. Lalezari | Chief Executive Officer | $1,833,398 |
| Tyler Blok | Chief Legal Officer | $1,391,299 |
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Jacob P. Lalezari | Chief Executive Officer | $783,850 |
| Tyler Blok | Chief Legal Officer | $532,494 |
| Robert E. Hoffman | Chief Financial Officer | $388,526 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dr. Lalezari | Chief Executive Officer | Resigned | 2026-10-19 |
| Robert E. Hoffman | Chief Executive Officer | Appointed | 2026-10-19 |
| Mr. Cohen | interim Chief Financial Officer | Resigned | 2025-05-06 |
| Robert E. Hoffman | Chief Financial Officer | Appointed | 2025-05-06 |
| Antonio Migliarese | CFO | Resigned | 2024-01-29 |
| Mitchell Cohen | Interim CFO | Appointed | 2024-01-29 |
| Jacob P. Lalezari, M.D. | Chief Executive Officer | Appointed | 2024-01-29 |
| Antonio Migliarese | interim President | Terminated | 2023-11-21 |
| Jacob P. Lalezari | interim CEO | Appointed | 2023-11-21 |
| Cyrus Arman | Senior Vice President, Business Operations | Appointed | 2023-07-11 |
| Cyrus Arman | President and principal executive officer | Resigned | 2023-07-11 |
| Antonio Migliarese | acting principal executive officer of the Company on an interim basis | Appointed | 2023-05-24 |
| Scott A. Kelly M.D. | Chief Medical Officer | Resigned | 2022-12-19 |
| Nitya G. Ray, Ph.D. | Chief Technology Officer | Resigned | 2022-11-25 |
| Stephen M. Simes | director | Appointed | 2022-10-19 |
| Scott A. Kelly, M.D. | director | Resigned | 2022-10-19 |
| Ryan Dunlap | director | Appointed | 2022-08-30 |
Leadership
- Dr. Jacob P. Lalezari CEO
- Jacob P. Lalezari CEO
- Jacob P. Lalezari, M.D. CEO
- Robert E. Hoffman CEO, CFO
- Tanya Durkee Urbach Chairman
- Mitchell Cohen CFO, Chief Accounting Officer
- Dr. Christopher P. Recknor, M.D. COO
- Arian Colachis General Counsel
- Alan P. Timmins Board Member
- Gordon A. Gardiner Board Member
- Jordon G. Naydenov Board Member
- Karen J. Brunke, Ph.D. Board Member
- Nader Z. Pourhassan, Ph.D Board Member
- Ryan Dunlap Board Member
- Samir R. Patel, M.D. Board Member
- Scott A Kelly, M.D. Board Member
- Stephen M. Simes Board Member